(NASDAQ: RPHM) Reneo Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Reneo Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RPHM's revenue for 2024 to be $1,312,484,408, with the lowest RPHM revenue forecast at $1,312,484,408, and the highest RPHM revenue forecast at $1,312,484,408. On average, 1 Wall Street analysts forecast RPHM's revenue for 2025 to be $797,151,063, with the lowest RPHM revenue forecast at $797,151,063, and the highest RPHM revenue forecast at $797,151,063.
In 2026, RPHM is forecast to generate $6,203,154,416 in revenue, with the lowest revenue forecast at $5,892,188,885 and the highest revenue forecast at $6,514,119,948.